From the reports discussed in Section 3.2 and Section 3.3 it is clear that the determination of MetHb and COHb is especially warranted when patients are treated with oxidizing drugs such as chloroquine and hydroxychloroquine. This is even more important when the patients have a confirmed G6PD deficiency.